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Objective: This review summarizes the treatment of Lennox-Gastaut syndrome, an intractable 
epileptic encephalopathy of early childhood. In particular, the review focuses on rufinamide, 
a recently released anticonvulsant medication with reported effectiveness in this epilepsy 
syndrome.
Methods: A systematic literature search (PubMed) was performed to review the existing 
literature pertaining to the treatment of Lennox-Gastaut syndrome as well as studies involving 
rufinamide as an anticonvulsant medication.
Results: The published literature to date documents a beneficial effect of rufinamide on children 
over 4 years old with Lennox-Gastaut syndrome. Studies indicate a significant decrease in tonic 
and atonic seizure frequency as well as total seizure frequency compared to placebo-treated 
children. Rufinamide appears to be well tolerated and a safe medication, somnolence and vomit-
ing being the most common side effects.
Conclusions: Rufinamide is a promising adjunctive therapy for Lennox-Gastaut syndrome, an 
intractable childhood epilepsy. To ensure its optimal effectiveness, clinicians must be familiar 
with the medication’s clinical response profile and potential for adverse effects.
Keywords: pediatric, epilepsy, epileptic encephalopathy, Lennox-Gastaut syndrome, 
rufinamide
Introduction – Lennox-Gastaut syndrome  
and its treatment
Lennox-Gastaut syndrome (LGS), one of the catastrophic epilepsies of childhood, is 
classified by the International League Against Epilepsy as a symptomatic generalized 
epilepsy syndrome. Originally described in 1966, this “epileptic encephalopathy” 
requires 3 components for diagnosis.1–4 First, children must exhibit multiple seizure 
types. Tonic seizures (especially during sleep), atonic (astatic or drop attacks) seizures, 
and atypical absence seizures are most commonly observed; some patients also develop 
myoclonic, generalized tonic-clonic, or partial seizures. Nonconvulsive status epilep-
ticus is quite frequent, occurring in over 50% of LGS patients. The second feature 
required by the definition is an interictal awake electroencephalogram (EEG) pattern 
consisting of slow spike wave discharges (less than 3 Hz), usually with a generalized 
distribution. Another characteristic EEG feature is paroxysms of low voltage fast 
activity at about 10 Hz during sleep. The third component of the definition of LGS is 
cognitive impairment involving moderate to severe mental retardation and behavioral 
disorders including aggression and autistic features. Neuropsychiatric Disease and Treatment 2009:5 548
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for drop attacks, atypical absences and myoclonic seizures in 
LGS.5,11,12 Although there are no controlled studies, valproic 
acid is reportedly effective against multiple LGS seizure types 
including atypical absence, myoclonic, and other situations in 
which slow spike-wave discharges are found on EEG. Caution 
must be exercised in using valproic acid in children under 
the age of 2 years, especially if they are receiving several 
other anticonvulsants, because of the risk of hepatotoxicity. 
In that age group, it has been recommended to try topiramate 
or lamotrigine first.11 Felbamate could also be considered as 
an alternative to valproic acid, because felbamate lacks the 
sedative side effect seen with other anticonvulsants (eg, topi-
ramate, benzodiazepines), which exacerbates seizure occur-
rence. Owing to the risk of aplastic anemia and hepatoxicity 
with felbamate use, this medication must be used with caution 
and appropriate patient monitoring of blood levels, liver func-
tion, and hematologic indices. Caretakers must be provided 
detailed information about the potential risks of felbamate. 
The effects of benzodiazepines are variable. A recent study 
showed that clobazam significantly reduced both drop and 
non-drop seizures in a dose-dependent manner in patients 
with LGS.13 Clobazam reportedly has less sedative effects 
than other benzodiazepines, making it an attractive potential 
adjunctive treatment for LGS.
An animal model of LGS does not exist, hampering 
progress in design of therapeutics. It is not surprising that 
there is no experimental model, since LGS comprises so 
many distinct seizure types and lacks a consistent underly-
ing etiology. Treatment of rats with a cholesterol synthesis 
blocker produces atypical absence seizures with slow spike 
waves, providing an opportunity to study the mechanism of 
this specific seizure type, which appears to involve GABAB 
receptors.14 These observations have not yet been exploited 
therapeutically.
Some general treatment considerations include recom-
mendations to use as few anticonvulsants concurrently 
as possible to avoid side effects from polytherapy, avoid 
excessive drowsiness which exacerbates several of the 
seizure types in this syndrome, and consider the cognitive 
and psychological comorbidities which result from both 
LGS and its treatment. Clearly, a multidisciplinary approach 
is required to address the medical and psychosocial aspects 
of LGS. At present, authorities recommend valproic acid 
as the first line medication, followed by one or two of the 
second-line agents (lamotrigine, rufinamide, topiramate, 
clobazam, felbamate, levetiracetam).5,12 If those therapies fail 
to achieve treatment goals, zonisamide, the ketogenic diet, 
vagus nerve stimulation, or corpus callosotomy can be tried 
Over 75% of children with LGS have an identifiable cause 
(symptomatic or presumed symptomatic/cryptogenic). These 
include numerous congenital or acquired etiologies, such as 
cortical maldevelopment, perinatal hypoxia-ischemia, CNS 
infection, or neurometabolic disorders. About 20% of chil-
dren with LGS have prior infantile spasms (West syndrome) 
and evolve into LGS with age. The typical age of onset of 
LGS is between 2 and 5 years; boys are affected about 5 times 
more often than girls.5 The prognosis of LGS is poor, with 
regard to both seizures and cognitive outcome. Risk factors 
for a poor cognitive prognosis include symptomatic etiology, 
history of nonconvulsive status epilepticus, prior infantile 
spasms, and early age of seizure onset.6
Due to the encephalopathic nature and multiple seizure 
types, LGS is notoriously difficult to treat.7 Many drugs 
reduce seizures initially, only to lose effectiveness over time. 
Children often end up on polypharmacy with numerous 
anticonvulsants, which adds to the cumulative side effects 
and drug–drug interactions.3 Furthermore, the seizures them-
selves are thought to contribute to the cognitive impairment 
and behavioral comorbidities.
Difficulties in diagnosing LGS are discussed in detail 
in a recent review.4 Sometimes the classic clinical and EEG 
features are not present at the onset of the syndrome. Due 
to the heterogeneous causes, the diagnosis may be delayed 
or uncertain, at least initially. Some aspects of the seizure 
semiology can be confusing. For example, it can be difficult 
to differentiate between spasms and tonic seizures and to 
identify and quantify atypical absence seizures accurately. 
Some rapidly secondarily generalized seizures can also mimic 
seizure types seen in LGS.
Many treatment attempts in LGS are anecdotal and 
empirical. Systematic difficulties complicate performance of 
drug trials in LGS, including the very frequent occurrence 
(often nearly uncountable) of atypical absence seizures, the 
inaccuracy of parental reports of seizure semiology and 
frequency, the wide range of etiologies, and the evolution of 
seizure types over time.
A few randomized, double blind, placebo-controlled trials 
of single agents have been performed in LGS.5,7 Felbamate,8 
lamotrigine,9 and topiramate10 reduced the occurrence of 
atonic and tonic-clonic seizures in children with LGS. All of 
these studies entailed addition of the study drug to other medi-
cations, and the studies varied considerably in their experi-
mental design and patient selection criteria. No head-to-head 
trial comparing more than one drug has been published.
Even with the new generation of anticonvulsants, valproic 
acid is considered the most useful initial medication of choice  Neuropsychiatric Disease and Treatment 2009:5 549
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(the latter targeting drop attacks). Of note, carbamazepine 
and gabapentin can exacerbate some of the seizure types in 
LGS.11,15 The role of newer anticonvulsants such as vigabatrin 
and zonisamide remain undetermined in LGS.
Rufinamide
Rufinamide  [1-(2,6-difluoro-phenyl)methyl-1H-
1,2,3-triazole-4-carboxamide] is a triazole derivative granted 
orphan drug status for the adjunctive treatment of LGS in 
the United States in 2004. It was released for use in Europe 
in 2007. In January 2009, rufinamide was approved by the 
United States Food and Drug Administration for treatment of 
LGS in children 4 years of age and older. It is also approved 
for adjunctive treatment of partial seizures in adults and 
adolescents.16 Rufinamide is structurally unrelated to other 
anticonvulsants. Its mechanism of action reportedly involves 
decreased firing of high frequency sodium-dependent action 
potentials and prolongation of sodium channel inactivation.17 
Enhancing sodium channel inactivation would prevent a 
neuron from generating subsequent bursts of high frequency 
action potentials. However, data implicating an effect of 
rufinamide on sodium channels is presently published only 
in abstract form and, given the preclinical profile, other 
mechanisms of action are likely to operate.18 Rufinamide has 
a wide spectrum of anticonvulsant effectiveness in animals 
including the maximal electroshock model (for generalized 
tonic-clonic and partial seizures) and the subcutaneous 
pentylenetetrazol model (for clonic seizures).19 In support of 
the hypothesized action of rufinamide on sodium channels, 
seizure protection in those in vivo models is also afforded 
by other anticonvulsants that block sodium channel function. 
Rufinamide also blocks seizures induced by subcutaneous 
strychnine, bicuculline, and picrotoxin.20
Rufinamide has an excellent safety profile in animals and 
lacks obvious cognitive side effects and behavioral toxicity at 
clinically relevant doses. On the rotorod test of motor coordi-
nation, rufinamide had a higher safety index than phenytoin, 
phenobarbital, and ethosuximide.19 The drug also appears to 
be relatively devoid of cognitive side effects in humans. In a 
multicenter study of 189 adolescent and adult patients with 
partial seizures, 12 weeks of treatment with rufinamide failed 
to cause deficits (compared to placebo) in several measures 
of cognitive function, including psychomotor speed and 
alertness, processing speed, and working memory.21
Pharmacokinetics
Taken orally, rufinamide is well absorbed (∼85% after an 
oral dose).22 The absorption rate is slow and the extent of 
absorption decreases as the dose is increased. After a single 
400 mg oral dose in healthy adults, the time to maximum 
plasma concentration ranges from 1.5 to 10 hours with an 
average of about 6 hours, with a mean maximum plasma 
concentration (Cmax) of 3.03 µg/mL.23 Rufinamide has 
low protein binding (∼34%) and food does not affect the 
time to maximum plasma concentration or peak plasma 
concentration.22 The plasma half life is 6 to 10 hours and is 
unaffected by renal disease. There is no reported effect of 
age on the half-life of rufinamide.
Rufinamide is eliminated primarily via metabolism, the 
principal metabolite being a carboxylic acid derivative. This 
metabolite primarily appears in the urine, and only about 2% 
of rufinamide occurs in the urine unchanged. The metabolite 
has no known pharmacological activity. The cytochrome 
P450 system is not involved.
Drug–drug interactions
The low plasma binding rate of rufinamide suggests that 
drug–drug interactions are likely to be minimal. However, 
in conditions like LGS, in which polypharmacy is usual, 
careful elucidation of drug–drug interactions is necessary. 
In all of the clinical trials with rufinamide, patients were on 
multiple anticonvulsants. In the largest trial of rufinamide 
in LGS, there were no significant effects of rufinamide on 
the plasma concentrations of valproic acid, lamotrigine, or 
topiramate.24 There is no study of the effects of rufinamide 
on felbamate concentration.
At average steady state concentrations of rufinamide, 
the pharmacokinetics of several other anticonvulsants 
were not significantly affected. This comparison includes 
population pharmacokinetic analyses of carbamazepine, 
lamotrigine, phenobarbital, phenytoin, and valproic acid. 
However, phenytoin clearance was decreased at average 
steady state levels of rufinamide up to 21%, suggesting that 
phenytoin levels should be closely monitored in patients 
on concurrent rufinamide.
The clearance of rufinamide is not significantly affected 
by several other anticonvulsants including carbamazepine, 
phenytoin, primidone, and phenobarbital. However, rufin-
amide clearance was decreased by valproic acid with elevated 
rufinamide levels of up to 70%.20 Therefore, valproic acid 
therapy should be introduced cautiously and at relatively low 
doses in children already on rufinamide.
Efficacy studies
Results from randomized controlled clinical trials of rufin-
amide are just appearing. Early sponsored studies, including  Neuropsychiatric Disease and Treatment 2009:5 550
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open label extensions, provided data that rufinamide had a 
beneficial effect as add-on therapy for partial seizures in ado-
lescents and adults. For LGS, a single double-blind random-
ized placebo controlled trial has been published.24 This study 
involved 138 patients between the ages of 4 and 30 years who 
had LGS diagnoses for a median of 7.5 years. About one-third 
of participants were under 12 years of age.
Study subjects were randomized to either oral rufinamide 
(titrated up to 45 mg/kg/day over 14 days) (N = 74) or placebo 
(N = 64) in addition to their other antiepileptic drugs. This 
study involved a 28-day baseline followed by an 84-day paral-
lel group treatment (14 days titration, 70 days maintenance). 
Primary end points were the percent change in seizure fre-
quency and the parent/guardian ratings of seizure severity.
The investigators found a significant decrease in 
total seizures compared with placebo (–32.7% vs –11.7%: 
P = 0.0015), and tonic-atonic seizures compared with 
placebo (–42.5% vs +1.4%: P  0.0001). The patients 
on rufinamide also had a greater improvement in seizure 
severity and a higher 50% responder rate compared with 
placebo for both total seizures and tonic-atonic seizures. 
Adverse effects in this study were modest, with 24% of 
treated patients experiencing sedation and 21% experiencing 
vomiting. Eight percent of the rufinamide group withdrew 
because of adverse side effects. Cognitive or psychiatric 
adverse events were less common among rufinamide-treated 
patients than in the placebo group. It was concluded that rufin-
amide is well tolerated and efficacious for seizures in LGS.
A 3-year open-label followup study, published in abstract 
form only, reports continued rufinamide effectiveness.25 That 
study included 124 patients treated for a median of 432 days 
at a dose of 10 to 45 mg/kg/day. Compared to the placebo 
group, there was a decrease in total seizures at all time points 
assessed up to 3 years, ranging from –42.6% to –79.3%. 
Furthermore, rufinamide was well tolerated over the long 
term, with only 12 patients discontinuing the drug because 
of adverse side effects (most commonly vomiting, pyrexia, 
and somnolence).
A recently published study from Europe, using obser-
vational retrospective data from multiple centers, examined 
the effectiveness of rufinamide in children and adults with 
refractory epilepsy, including LGS.26 In the subgroup with 
LGS, 17 of 31 patients (55%) had a response rate with greater 
than 50% reduction in countable seizures. Investigators found 
fatigue, vomiting, anorexia in 10% to 20% of patients but 
no serious adverse effects. Again, this study concludes that 
rufinamide is effective and well tolerated in patients with 
refractory epilepsy, including LGS.
Although promising as a novel anticonvulsant in LGS, 
several caveats arise regarding rufinamide. In part, issues 
relate to the study populations. As discussed above, patients 
with LGS are notoriously difficult to treat, are often treated 
with multiple anticonvulsant medications, and seizures are 
of several different types and difficult to monitor and count. 
Therefore, the question arises as to what place rufinamide 
will hold in overall treatment algorithm for LGS. The drug 
is promising with good effectiveness and tolerability studies 
to date. However, a larger number of patients must be treated 
with this medication to establish its role in the treatment 
armamentarium. There are no head-to-head studies compar-
ing rufinamide with other anticonvulsants. The role of this 
new medication in relationship to prior drugs with some 
reported effectiveness in LGS needs to be further defined.
Conclusions
Rufinamide is a novel, broad-spectrum anticonvulsant drug 
with promising potential for treatment of many seizure types. 
In particular, the multiple seizure types seen in patients 
with LGS may be amenable to treatment with rufinamide. 
Rufinamide appears to have a good safety profile and is well 
tolerated with minimal expected side effects. Some of the 
most common side effects (eg, somnolence, vomiting) could 
perhaps be ameliorated by slow titration. Patient and caretaker 
satisfaction data need to be obtained. Given the devastating 
nature of the seizures and cognitive impairments in LGS, any 
treatment with an even modest benefit is a welcome addition 
to the therapeutic armamentarium.
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